8-K: ICU Medical Reports Q4 2025 Results, Issues 2026 Guidance

ICU Medical announced its fourth quarter 2025 financial results, reporting a revenue decline to $540.7 million and a GAAP net loss of $(15.7) million, while providing fiscal year 2026 guidance.

Summary

• Fourth quarter 2025 revenue was $540.7 million, a decrease from $629.8 million in the same period in the prior year.
• GAAP gross profit for Q4 2025 was $203.0 million, down from $227.3 million in Q4 2024, but GAAP gross margin improved to 38% from 36%.
• GAAP net loss for Q4 2025 narrowed to $(15.7) million, or $(0.64) per diluted share, compared to a GAAP net loss of $(23.8) million, or $(0.97) per diluted share, for Q4 2024.
• Adjusted diluted earnings per share for Q4 2025 was $1.91, a decrease from $2.11 for Q4 2024.
• Adjusted EBITDA was $98.2 million for Q4 2025, down from $105.5 million for Q4 2024.
• The Vital Care product line experienced a significant revenue decrease of $110.3 million in Q4 2025, primarily due to the disposal of the IV Solutions business on May 1, 2025.
• Consumables revenue increased by $16.6 million to $284.7 million in Q4 2025, and Infusion Systems revenue increased by $4.6 million to $176.3 million.
• For fiscal year 2026, the company estimates GAAP net income to be in the range of $26 million to $44 million and GAAP net earnings per share between $1.03 and $1.74.
• Fiscal year 2026 guidance for adjusted EBITDA is in the range of $400 million to $430 million, and adjusted EPS is expected to be between $7.75 and $8.45.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral-to-slightly positive report. While revenue and adjusted EPS declined year-over-year, the GAAP net loss narrowed, gross margin improved, and results were in line with expectations, with a clear outlook for 2026.

Positives

• GAAP gross margin improved to 38% in Q4 2025 from 36% in Q4 2024.
• GAAP net loss narrowed to $(15.7) million in Q4 2025 from $(23.8) million in Q4 2024, representing a significant improvement.
• Consumables revenue increased by $16.6 million to $284.7 million in Q4 2025 compared to Q4 2024.
• Infusion Systems revenue increased by $4.6 million to $176.3 million in Q4 2025 compared to Q4 2024.
• Net cash provided by operating activities for the twelve months ended December 31, 2025, was $179.8 million.
• Proceeds from the sale of business were $211.2 million for the twelve months ended December 31, 2025.

Negatives

• Total revenue decreased by $89.1 million in Q4 2025 to $540.7 million from $629.8 million in Q4 2024.
• GAAP gross profit decreased to $203.0 million in Q4 2025 from $227.3 million in Q4 2024.
• Adjusted diluted EPS decreased to $1.91 in Q4 2025 from $2.11 in Q4 2024.
• Adjusted EBITDA decreased to $98.2 million in Q4 2025 from $105.5 million in Q4 2024.
• Vital Care revenue significantly declined by $110.3 million in Q4 2025 due to the disposal of the IV Solutions business.
• Total GAAP revenue for the full year 2025 decreased by $150.7 million to $2,231.3 million from $2,382.0 million in 2024.

Risks

• Risks from doing business in foreign countries, including related to tariffs and other barriers to trade.
• Ability to compete successfully, including with larger international companies and established local companies.
• Decreased demand for products.
• Costs related to product development.
• Cost volatility or potential loss of supply of raw materials due to dependence on single and limited source third-party suppliers.
• Ability to achieve operating efficiencies.
• Risks related to significant sales through distributors.
• Inflation and foreign currency exchange rates.
• Impacts from global macroeconomic and geopolitical conditions.
• Healthcare costs and reimbursement levels.
• Disruptions at the FDA and other governmental agencies.
• Damage at manufacturing or supply facilities.
• Risks associated with the IV Solutions joint venture and the Smiths Medical integration.
• Risks associated with the timing and resolution of the 2025 warning letter.
• Risks related to protection of information technology systems and compliance with privacy laws and regulations.
• Risks related to intellectual property.

Future Outlook

For fiscal year 2026, ICU Medical estimates GAAP net income to be in the range of $26 million to $44 million and GAAP net earnings per share between $1.03 and $1.74. The company also expects adjusted EBITDA to be in the range of $400 million to $430 million and adjusted EPS between $7.75 and $8.45.

Management Comments

• Vivek Jain, ICU Medical's Chief Executive Officer, stated, "Fourth quarter results were generally in line with our expectations."

Industry Context

StockSavvy.ai notes that the medical products industry, particularly infusion systems and critical care, is subject to evolving healthcare costs, reimbursement levels, and regulatory scrutiny. ICU Medical's performance reflects the impact of strategic divestitures, such as the IV Solutions business, which can temporarily depress top-line revenue but may streamline operations for long-term focus. The company's guidance for 2026 suggests a period of stabilization and potential growth following these adjustments.

Stakeholder Impact

• Shareholders: Impacted by revenue decline, but also by improved GAAP net loss and positive future guidance. The disposal of the IV Solutions business affects revenue composition.
• Customers: Continued provision of infusion systems, consumables, and critical care products.
• Employees: Potential impact from restructuring and strategic transactions, though not explicitly detailed in terms of job changes.

Next Steps

• Host a conference call on February 19, 2026, at 4:30 p.m. ET (1:30 p.m. PT) to discuss Q4 and full year 2025 financial results.
• Continue to operate in the global infusion systems, infusion consumables, and high-value critical care products markets.

Key Dates

Recommendation

The company's Q4 2025 results show a mixed picture with revenue and adjusted EBITDA declines, largely influenced by a strategic divestiture. However, the GAAP net loss narrowed, and gross margin improved. The provided 2026 guidance offers a clear path forward, suggesting stabilization and potential for future growth. Given the strategic adjustments and the 'in line with expectations' commentary, a 'hold' recommendation is appropriate as the market digests the impact of the divestiture and evaluates the execution against the 2026 outlook.

Keywords

ICU Medical, ICUI, Q4 2025 Earnings, Fiscal Year 2026 Guidance, Medical Products, Infusion Systems, Consumables, Vital Care, Financial Results, SEC Filing, Healthcare, Medical Devices